Status:
UNKNOWN
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
Lead Sponsor:
Ministry of Health, Labour and Welfare, Japan
Conditions:
Heparin-Induced Thrombocytopenia
Eligibility:
All Genders
20+ years
Brief Summary
Several clinical studies in Western countries have revealed that the prevalence of HIT is 0.5 to 5%, varying depending on the clinical setting. Thirty to 50% of HIT patients suffer from thromboembolic...
Detailed Description
Heparin is an important anticoagulation treatment, especially for cardiovascular patients. Recently, heparin-induced thrombocytopenia type II (HIT) has been shown to be an immune-mediated, life-threat...
Eligibility Criteria
Inclusion
- Adult males or females who meet the criteria listed below:
- Patients who are \>=20 years of age
- Patients scheduled to undergo cardiovascular surgery or patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention
- Patients willing and able to give informed consent
Exclusion
- Patients who have a documented history of heparin-induced thrombocytopenia
- Chronic thrombocytopenia (\<100,000/μL)
- Hematopoietic malignancy
- Patients who receive an anticancer drug
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
End Date :
March 1 2006
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00198575
Start Date
November 1 2004
End Date
March 1 2006
Last Update
February 16 2006
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagoya Daini Red Cross Hospital
Nagoya, Aichi-ken, Japan
2
Nagoya University Hospital
Nagoya, Aichi-ken, Japan
3
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
4
National Hospital Organization Hakodate National Hospital
Hakodate, Hokkaido, Japan